WE PERCEIVE. WE PREPARE. WE PROTECT.

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

Emergent has entered into an agreement with Hikma Pharmaceuticals to obtain the exclusive distribution rights to KLOXXADO® (naloxone HCl) Nasal Spray 8 mg.

LEARN MORE

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading The New Way Forward for public health.

Learn more

Capabilities

We are a leader in providing solutions that address public health threats and bring lifesaving, life-extending products to market.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    Emergent specializes in developing, manufacturing, and stockpiling medical countermeasures for military and civilian populations that target some of the deadliest public health threats.

  • Bioservices

    Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations.

Woman in Lab

At Emergent, our mission is to protect and enhance life.

View our 2023 Annual Report

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1 This six-year agreement complements and strengthens Emergent’s mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths —providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education.
Read More

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga™ (ansuvimab-zykl). Ebanga™ is indicated for the treatment of infection caused by Zaire Ebola virus.
Read More

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST.
Read More
READ ALL NEWS

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.